Abstract: The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.

Abstract: Provided are a pharmaceutical composition for preventing or treating cervical cancer including gypenoside LXXV or a pharmaceutically acceptable salt thereof as an active ingredient, a method of preventing or treating cervical cancer including administering the pharmaceutical composition to a subject excluding humans, a health functional food composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient, and a feed composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient.

Abstract: The present invention relates to a method for mass production of ginsenoside Rh2-Mix. The present invention includes treating PPD-Mix with an organic acid and heat to obtain Rg3-Mix and treating the obtained Rg3-Mix using a recombinant GRAS strain in the Rg3-Mix to produce Rh2-Mix, and thereby facilitates the mass production of ginsenoside Rh2-Mix using ?-glucosidase, which has been known to be difficult. Further, the present invention is advantageous in that the Rh2-Mix can be produced in high yield even at high temperatures, and mass production thereof for industrial purposes is practical as the production process is simple and more economical than direct use of an enzyme.

Abstract: The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.

Abstract: Provided are a pharmaceutical composition for preventing or treating cervical cancer including gypenoside LXXV or a pharmaceutically acceptable salt thereof as an active ingredient, a method of preventing or treating cervical cancer including administering the pharmaceutical composition to a subject excluding humans, a health functional food composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient, and a feed composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient.

Abstract: Provided are a method of producing minor ginsenosides using a ginsenoside glycosidase protein derived from a Microbacterium sp. (Microbacterium testaceum) microorganism, and a composition including the protein for conversion into minor ginsenosides. The ginsenoside glycosidase exhibits very excellent activity of specifically hydrolyzing a sugar at the C-6 position of ginsenoside to convert the ginsenoside into in-vivo absorbable minor ginsenoside, thereby being very usefully applied to mass-production of ginsenoside.

Abstract: Provided are a method of producing minor ginsenosides using a ginsenoside glycosidase protein derived from a Microbacterium sp. (Microbacterium testaceum) microorganism, and a composition including the protein for conversion into minor ginsenosides. The ginsenoside glycosidase exhibits very excellent activity of specifically hydrolyzing a sugar at the C-6 position of ginsenoside to convert the ginsenoside into in-vivo absorbable minor ginsenoside, thereby being very usefully applied to mass-production of ginsenoside.

Abstract: The present invention relates to Rhodanobacter ginsenosidimutans KCTC22231T-derived ginsenoside glycosidase and use thereof. The polypeptide has an activity of converting PPD (protopanaxadiol)-type saponins into in vivo absorbable and highly active deglycosylated saponins, by selective hydrolysis of a bond at a particular position of ginsenoside. The present invention also relates an amino acid sequence constituting the polypeptide, a nucleic acid sequence encoding the protein, a recombinant vector comprising the nucleic acid sequence, and a transformant transformed with the vector. The invention further provides a method for preparing Rhodanobacter ginsenosidimutans KCTC22231T-derived ginsenoside glycosidase by culturing the transformant, a method for converting PPD (protopanaxadiol)-type major ginsenoside into a rare ginsenoside that is absorbable in vivo using the protein, and a composition for converting PPD-type saponins into in vivo absorbable saponins, having the protein as an active ingredient.

Abstract: The present invention relates to Rhodanobacter ginsenosidimutans KCTC22231T-derived ginsenoside glycosidase and use thereof, and this protein has an activity of converting PPD (protopanaxadiol)-type saponins into in vivo absorbable, highly active deglycosylated saponins by selective hydrolysis of a bond at a particular position of ginsenoside. More particularly, the present invention relates to an amino acid sequence constituting the protein, a nucleic acid sequence encoding the protein, a recombinant vector comprising the nucleic acid sequence, a transformant transformed with the vector, a method for preparing Rhodanobacter ginsenosidimutans KCTC22231T-derived ginsenoside glycosidase by culturing the transformant, a method for converting PPD (protopanaxadiol)-type major ginsenoside into a rare ginsenoside that is absorbable in vivo using the protein, and a composition for converting PPD-type saponins into in vivo absorbable saponins, comprising the protein as an active ingredient.